© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
April 14, 2021
Opinions are diverse on how best to clear the obstructions to biosimilar market entry and patient access.
April 13, 2021
April 12, 2021
April 11th 2021
This is part 1 of a series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.
April 10th 2021
By Paul Cornes, BM, BCH, MA, MRCP, FRCR
An internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
April 9th 2021
The latest e-book from The Center for Biosimilars® offers insightful content on patient education, biosimilar development, and regulatory issues.
By Tony Hagen
Next-stage biosimlar acceptance will stand on the strength and availability of real-world data as more of these biologics are launched, a Community Oncology Alliance (COA) conference panel said.
Here are the top 5 biosimilar articles for the week of April 5, 2021.
April 8th 2021
Calls for price regulation and lopsided incentives are threats to biosimilar progress, Community Oncology Alliance (COA) Executive Director Ted Okon argues.
April 7th 2021
Richard G. Frank, PhD, and Meaghan Rose Smith discuss a recent white paper on the regulatory and anticompetitive impediments to biosimilar market entry and the hope for biosimilar savings.
PlantForm will use tobacco plants to develop antibodies for its checkpoint inhibitor pembrolizumab biosimilar.
April 6th 2021
Shanghai Henlius Biotech began as a 2-person enterprise in 2010 and now has multiple oncology products in development and 3 biosimilars on the market. An executive discusses its business trajectory.
April 5th 2021
By Deana Ferreri, PhD
India has tightened up guidelines for biosimilar development in a quest to achieve standards equivalent to those in Europe and the United States.